{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002147","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.583432+00:00","generated_at":"2026-05-23T17:49:00.819898+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCryst CFO Anthony Doyle resigns; CEO Stonehouse takes interim CFO role","bullets":["CFO Anthony Doyle resigns effective April 9, 2025; will provide transition consulting at $450/hour until May 31.","CEO Jon P. Stonehouse appointed Interim CFO and Interim Principal Accounting Officer effective April 9.","Company hired former public biotech CFO as financial consultant to support Stonehouse during CFO search.","No change to Stonehouse's compensation arrangements resulting from the interim appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002147","json":"https://secwatch.observer/filing/0001171843-25-002147.json","markdown":"https://secwatch.observer/filing/0001171843-25-002147.md","text":"https://secwatch.observer/filing/0001171843-25-002147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/f8k_040625.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T17:49:00.819898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c248291037","claim":"Anthony Doyle resigned as Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"e8eeeefc38","claim":"Jon P. Stonehouse was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer and Interim Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}